Gaurav Aggarwal, M.D.

Managing Partner at Vivo Capital · Joined 2016

View Live Interactive Profile →

Biography

Gaurav Aggarwal is a Managing Partner of Vivo Capital. Vivo's biography states he has been an investor in the life sciences sector for more than twenty years and that he rejoined Vivo as a Managing Partner in April 2024, having previously been a Managing Director from 2016 to 2023 and Chief Investment Officer for the firm's U.S. public investment fund from 2021 to 2023. Before Vivo he was Chief Business Officer of Ocera Therapeutics, Inc. from April 2014 to October 2016, Managing Director of Investor Growth Capital during 2013, and a General Partner at the venture capital fund Panorama Capital, L.P. from August 2006 to December 2012; earlier he was an associate with JPMorgan Partners, LLC. He was quoted as Managing Partner in Vivo's 7 May 2025 announcement of the close of the third cycle of the Vivo Opportunity Fund. No current board seat is recorded: Vivo's biography states he has served on the boards of Unicycive Therapeutics and Geron since March 2023 and November 2023, but Geron's proxy statement filed 7 April 2026 states he resigned from the Geron board effective 10 October 2025 and describes him as a former director, and Unicycive's proxy statement filed 30 April 2026 states he resigned as a director on 6 April 2026. No degree-granting institution is published for him, so education is left empty.

Previous Experience

Notable Investments

Unicycive Therapeutics, Inc. UNCYGeron Corporation GERN

Career Timeline

2006
Becomes a General Partner at Panorama Capital, L.P., a venture capital fund (August 2006 to December 2012).
2013
Serves as Managing Director of Investor Growth Capital (January to December 2013).
2014
Becomes Chief Business Officer of Ocera Therapeutics, Inc. (April 2014 to October 2016).
2016
Joins Vivo Capital as a Managing Director.
2021
Becomes Chief Investment Officer for Vivo's U.S. public investment fund (2021 to 2023).
2023
Joins the board of Unicycive Therapeutics in March 2023 and the board of Geron in November 2023.
2024
Rejoins Vivo Capital as a Managing Partner in April 2024.
2025
Quoted as Managing Partner in Vivo's 7 May 2025 announcement of the close of the third cycle of the Vivo Opportunity Fund.
2025
Resigns from the board of directors of Geron Corporation effective 10 October 2025, per Geron's 2026 proxy statement.
2026
Resigns as a director of Unicycive Therapeutics on 6 April 2026, per Unicycive's 2026 proxy statement.

Sources & References

Vivo Capital - Our Team, Gaurav Aggarwal biography ↗SEC EDGAR - Geron Corporation DEF 14A filed 7 April 2026 (resignation effective 10 October 2025) ↗Geron Corporation - Leadership and board page (Aggarwal not listed) ↗SEC EDGAR - Unicycive Therapeutics DEF 14A filed 30 April 2026 (resignation 6 April 2026) ↗Vivo Capital - Closes Its Public Fund with Commitments of Over $740 Million, 7 May 2025 ↗